• Explore /
  • Poster
  • / Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.

Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.

Abstract Poster

Authors

Martin Dreyling

Martin H. Dreyling

LMU University Hospital, Munich, Germany

Martin H. Dreyling , Armando Santoro , Sirpa Leppä , Judit Demeter , George Follows , Georg Lenz , Won Seog Kim , Luigina Mollica , Arnon Nagler , Colin Phipps Diong , Mariano Provencio , Massimo Magagnoli , Atanas Radinoff , Javier Munoz , Anjun Cao , Florian Hiemeyer , Fatuma Odongo , Jose E. Garcia-Vargas , Barrett H. Childs , Pier Luigi Zinzani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT01660451

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7555)

DOI

10.1200/JCO.2023.41.16_suppl.7555

Abstract #

7555

Poster Bd #

106

Abstract Disclosures

Similar Posters

First Author: Andrew David Zelenetz

First Author: Lorenzo Falchi

First Author: Ruemu Ejedafeta Birhiray

First Author: Ian W. Flinn